ProfoundBio discovers the joys of having a wealthy owner
The company has become the latest in a recent string of China-related innovative drug makers to be purchased by larger foreign buyers Key Takeaways: Cancer treatment maker ProfoundBio announced it…
PODCAST: A Biotech Buyout, and an Influencer Uprising
By Doug Young & Rene Vanguestaine AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will…
CHINA BULLETIN: PMI Readings Signal Strong End to 2023
In this week’s issue New Year’s travel bounces back, Wanda sells off shopping malls and a top influencer topples a CEO. On a scale of 1 to 100, we give…
Gracell Bio Shares Tumble as Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
Receipt of ‘orphan drug’ designation for company’s CAR-T cancer drug in the U.S. will bring financial incentives, but also underscores drug’s limited market potential Key takeaways Gracell Bio stands to…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
- Innogen Pharma jostles for a slice of the weight-loss market
